(RDNT) RadNet - Overview
Stock: Imaging, Centers, Digital, Health
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 46.0% |
| Relative Tail Risk | -7.14% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.29 |
| Alpha | -14.36 |
| Character TTM | |
|---|---|
| Beta | 1.132 |
| Beta Downside | 0.856 |
| Drawdowns 3y | |
|---|---|
| Max DD | 46.84% |
| CAGR/Max DD | 1.07 |
Description: RDNT RadNet January 10, 2026
RadNet, Inc. (NASDAQ:RDNT) operates a network of outpatient diagnostic imaging centers across the United States and internationally, organized into two primary segments: Imaging Centers and Digital Health. The firm delivers a full suite of imaging modalities-including MRI, CT, PET, nuclear medicine, mammography, ultrasound, and fluoroscopy-and offers multi-modality services that support radiology workflows.
Beyond traditional imaging, RadNet develops and markets a portfolio of digital health solutions: picture-archiving-communication systems (PACS), cloud-native image distribution platforms, and AI-driven interpretation tools for breast, lung, and prostate cancers. Its DeepHealth OS integrates these capabilities into a single operating system designed to improve radiology efficiency, quality, and patient outcomes. The company was founded in 1981 and is headquartered in Los Angeles, California.
Recent data (FY 2023) show revenue of approximately $1.2 billion, with a 5 % year-over-year increase in imaging volume-driven largely by the aging U.S. population and a continued shift from inpatient to outpatient imaging settings. AI adoption is accelerating; RadNet’s AI suite now processes roughly 30 % of its breast-cancer screenings, a figure that industry analysts expect to double within two years as reimbursement models increasingly reward diagnostic accuracy. A key sector driver is Medicare’s prospective payment adjustments, which can compress margins but also incentivize efficiency-focused technologies like DeepHealth OS.
For a deeper, data-rich assessment of RadNet’s valuation metrics and peer comparison, you might find ValueRay’s analytical tools useful.
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income: -12.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA -1.46 > 1.0 |
| NWC/Revenue: 25.53% < 20% (prev 30.80%; Δ -5.27% < -1%) |
| CFO/TA 0.07 > 3% & CFO 257.2m > Net Income -12.7m |
| Net Debt (1.04b) to EBITDA (239.8m): 4.35 < 3 |
| Current Ratio: 1.87 > 1.5 & < 3 |
| Outstanding Shares: last quarter (74.7m) vs 12m ago -0.61% < -2% |
| Gross Margin: 11.43% > 18% (prev 0.14%; Δ 1130 % > 0.5%) |
| Asset Turnover: 56.76% > 50% (prev 54.13%; Δ 2.63% > 0%) |
| Interest Coverage Ratio: 1.32 > 6 (EBITDA TTM 239.8m / Interest Expense TTM 69.9m) |
Altman Z'' 0.96
| A: 0.14 (Total Current Assets 1.08b - Total Current Liabilities 574.9m) / Total Assets 3.67b |
| B: -0.03 (Retained Earnings -94.8m / Total Assets 3.67b) |
| C: 0.03 (EBIT TTM 92.5m / Avg Total Assets 3.47b) |
| D: -0.04 (Book Value of Equity -88.9m / Total Liabilities 2.35b) |
| Altman-Z'' Score: 0.96 = BB |
Beneish M -2.93
| DSRI: 0.83 (Receivables 210.5m/229.3m, Revenue 1.97b/1.77b) |
| GMI: 1.22 (GM 11.43% / 13.95%) |
| AQI: 1.07 (AQ_t 0.31 / AQ_t-1 0.29) |
| SGI: 1.11 (Revenue 1.97b / 1.77b) |
| TATA: -0.07 (NI -12.7m - CFO 257.2m) / TA 3.67b) |
| Beneish M-Score: -2.93 (Cap -4..+1) = A |
What is the price of RDNT shares?
Over the past week, the price has changed by -1.23%, over one month by -10.50%, over three months by -12.25% and over the past year by +7.58%.
Is RDNT a buy, sell or hold?
- StrongBuy: 5
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the RDNT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 91.8 | 32.5% |
| Analysts Target Price | 91.8 | 32.5% |
| ValueRay Target Price | 87.3 | 26% |
RDNT Fundamental Data Overview February 03, 2026
P/B = 5.1624
P/EG = 2.32
Revenue TTM = 1.97b USD
EBIT TTM = 92.5m USD
EBITDA TTM = 239.8m USD
Long Term Debt = 1.07b USD (from longTermDebt, last quarter)
Short Term Debt = 85.8m USD (from shortTermDebt, last quarter)
Debt = 1.85b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.04b USD (from netDebt column, last quarter)
Enterprise Value = 6.46b USD (5.42b + Debt 1.85b - CCE 804.7m)
Interest Coverage Ratio = 1.32 (Ebit TTM 92.5m / Interest Expense TTM 69.9m)
EV/FCF = 124.1x (Enterprise Value 6.46b / FCF TTM 52.1m)
FCF Yield = 0.81% (FCF TTM 52.1m / Enterprise Value 6.46b)
FCF Margin = 2.64% (FCF TTM 52.1m / Revenue TTM 1.97b)
Net Margin = -0.65% (Net Income TTM -12.7m / Revenue TTM 1.97b)
Gross Margin = 11.43% ((Revenue TTM 1.97b - Cost of Revenue TTM 1.74b) / Revenue TTM)
Gross Margin QoQ = 13.86% (prev 13.88%)
Tobins Q-Ratio = 1.76 (Enterprise Value 6.46b / Total Assets 3.67b)
Interest Expense / Debt = 0.94% (Interest Expense 17.4m / Debt 1.85b)
Taxrate = 31.49% (6.38m / 20.3m)
NOPAT = 63.4m (EBIT 92.5m * (1 - 31.49%))
Current Ratio = 1.87 (Total Current Assets 1.08b / Total Current Liabilities 574.9m)
Debt / Equity = 1.75 (Debt 1.85b / totalStockholderEquity, last quarter 1.06b)
Debt / EBITDA = 4.35 (Net Debt 1.04b / EBITDA 239.8m)
Debt / FCF = 20.03 (Net Debt 1.04b / FCF TTM 52.1m)
Total Stockholder Equity = 947.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -0.37% (Net Income -12.7m / Total Assets 3.67b)
RoE = -1.34% (Net Income TTM -12.7m / Total Stockholder Equity 947.8m)
RoCE = 4.58% (EBIT 92.5m / Capital Employed (Equity 947.8m + L.T.Debt 1.07b))
RoIC = 3.16% (NOPAT 63.4m / Invested Capital 2.00b)
WACC = 7.69% (E(5.42b)/V(7.27b) * Re(10.09%) + D(1.85b)/V(7.27b) * Rd(0.94%) * (1-Tc(0.31)))
Discount Rate = 10.09% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 4.89%
[DCF Debug] Terminal Value 79.05% ; FCFF base≈68.9m ; Y1≈67.9m ; Y5≈69.7m
Fair Price DCF = 3.44 (EV 1.31b - Net Debt 1.04b = Equity 265.9m / Shares 77.3m; r=7.69% [WACC]; 5y FCF grow -2.37% → 2.90% )
EPS Correlation: 6.15 | EPS CAGR: 15.16% | SUE: -2.33 | # QB: 0
Revenue Correlation: 99.12 | Revenue CAGR: 12.77% | SUE: 3.15 | # QB: 6
EPS next Quarter (2026-03-31): EPS=-0.04 | Chg30d=+0.023 | Revisions Net=-1 | Analysts=4
EPS next Year (2026-12-31): EPS=0.78 | Chg30d=+0.002 | Revisions Net=-1 | Growth EPS=+106.8% | Growth Revenue=+11.8%